Genotype distribution of IL-18 genotypes [-607C > A] and [-137 G > C]
Susceptibility to HBV disease progression might be influenced by SNPs in the cytokine genes. So, we analyzed genotypic distribution of IL-18 genotypes in different categories of subjects. Genotypic distribution for IL-18 (-607) showed that genotype CA was the most common among all groups. Genotype CC of IL-18 (-607)was present maximally (67%) in HBV-cirrhotic subjects and found to be the least in inactive carrier subjects. HBV -HCC subjects had maximum distribution of AA genotype as compared to other groups (Table 1).
Table 1.Genotype and allele distribution of among different categories of subjects of IL-18 (-607)
genotypes and its association with HBV-HCC risk
Groups
|
Healthy Controls
(n=102)
|
Inactive carrier
(n=81)
|
Hepatitis
(n=74)
|
Cirrhosis
(n=67)
|
HCC
(n=72)
|
|
|
|
|
|
|
Genotypic frequency
|
|
|
|
|
|
CC
|
45 (44.12)
|
22 (27.16)
|
30(40.55 )
|
44 (67)
|
40 (55.56)
|
CA
|
57 (55.88)
|
57 (70.37)
|
42 (56.75)
|
19 (29.23)
|
27(44.82)
|
AA
|
NIL
|
2 (2.47)
|
2 (2.70)
|
2 (3.07)
|
5(6.94)
|
Allele Frequency
|
|
|
|
|
|
C Allele
|
147(72.05)
|
101(62.34)
|
102(68.92)
|
107(82.31)
|
107(74.31)
|
A Allele
|
57(27.95)
1(REF)
|
61(37.66)
----
1( REF )
|
46(31.08)
1.1
(0.63- 1.94)
0.54* (0.3-0.98)
|
23(17.69)
OR (CA)
0.34***
(0.19- 0.62)
0.17*** ǂ
(0.09-0.31)
|
37(25.69)
0.64
(0.36- 1.11)
0.31***ǂ
(0.17-0.56)
|
Data represented as number of subjects (genotypic distribution. %).Data represented as Odd’s ratio (95% confidence interval) ;.*** p<0.001 w.r.t control ;ǂ ***p<0.001 w.r.t inactive carrier; *p<0.05 w.r.t inactive carrier.
Genotypic distribution for IL-18(-137) revealed that GG genotype was the most prevalent one among all groups. IL-18(-137) GC genotype was present maximally in Chronic active hepatitis (50%) subjects and found to be the least in HBV-cirrhotic subjects. However, HBV cirrhotic subjects showed the highest distribution of CC genotype as compared to other groups [Table 2].
Table 2
Genotype and allele distribution of among different categories of subjects of IL-18 (-137) genotypes and its association with HBV-HCC risk
Groups | Healthy Controls (n = 72) | Inactive carrier (n = 72) | Hepatitis (n = 78) | Cirrhosis (n = 70) | HCC (n = 61) |
Genotypic frequency | | | | | |
GG | 47 (65.27 ) | 42 (58.33 ) | 35 (44.87 ) | 46(65.71) | 34(55.74) |
G C | 23 (31.94 ) | 28 (38.88 ) | 39 (50 ) | 20(28.57) | 25(40.99) |
CC | 2 (2.7 ) | 2 (2.77 ) | 4 (5.12 ) | 4 (5.71 ) | 2 (3.28 ) |
Allele Frequency | | | | | |
G Allele | 117(81.25) | 112(77.78) | 109(69.87) | 112(80) | 93(76.23) |
C Allele | 27(18.75) 1( REF) 1 (REF) | 32(22.22) --- 1( REF) --- 1( REF) | 47(30.13) 2.3** (1.3–4.1) 1.67 (0.94–2.9) 2.76 (0.6-12.64) 2.5 (0.54–11.320) | 28(20) OR(GC) 0.89 (0.48–1.68) 0.659 (0.36–1.18) OR (CC) 2.1 (0.47–9.3) 1.9 (0.42–8.33) | 29(23.77) 1.5 (0.84–2.7) 1.1 (0.62–1.95) 1.42 (0.27–7.4) 1.27 (0.24–6.63) |
Data represented as number of subjects (genotypic distribution.%). Data represented as Odd’s ratio (95% confidence interval) ; ** p < 0.01 w.r.t control |
Association of IL-18 genotypes (-607C > A) and (-137 G > C) with HBV- HCC risk
As presented in table 1, the odd’s ratio for IL-18 (-607) genotype association with HBV disease progression showed genotype CA as a protective factor for HBV-cirrhotic subjects among controls. Also, this genotype was found to be protective for hepatitis [1.8 fold], cirrhosis [5.8
fold] and HBV-HCC (3.2 fold) subjects among HBV inactive carriers. However, no significant association for AA genotype was noticed. The odd’s ratio for the association between IL-18 (-137) genotypes and the advancement in disease showed that genotype GC as a significant risk factor for the chronic active hepatitis with control as a reference. Also, CC genotype was found to be a 2.7- and 2.5- fold risk for the HBV-hepatitis development among controls and carriers
respectively albeit non-significantly as shown in Table 2.
Association between IL-18 genotypes (-607C > A) and (-137 G > C) and HBV DNA load
Further exploration for association between IL-18 genotypes and HBV-DNA load was carried out. All the cases were categorized into two sub-groups based on HBV DNA load (> 10− 3and < 10− 3 IU/dL). The distribution characteristics of gene polymorphisms in the two groups are summarized in Table 3 .None of the genotypes studied showed any significant association with HBV DNA load.
Table 3.Association of IL-18( -137 & -607) genotypes with HBV DNA load
HBV-DNA LOAD
/(IU/DL)
Polymorphisms >10-3 <10-3 χ 2 p-value OR 95%CI
|
|
IL-18(- 607)
CC 37 54 0 .510 0.510 1.202 0 .695-2.079
CA 55 59 0.117 0.177 0.647 0 .375-1.116
AA 1 9 0.030 <.05 7.327 0.912-58.901
IL -18(-137)
GG 44 69 0 .462 0.462 1.217 0 .721-2.005
CG 46 61 0 .645 0.645 0 .884 0 .524-1.493
CC 6 6 0 .534 0.534 0.692 0.216 -2.215
|
HBV-DNA <1×10-3 IU/mL; HBV-DNA ≥1×10-3 IU/mL. p-value obtained from χ 2 test. AA compared with both CC and CA;* p<0.05.
Association between IL-18 genotypes [-607C > A] & [-137G > C] and HBeAG status
The status of HBeAg is very important in disease development from CHB to HCC. So we investigated association between genotype of IL-18 with HBeAg status. As shown in Table 4, the genotypes CC and CA of IL-18 (-607) showed significant (p < 0.001) positive association and significant (p < 0.001) negative association respectively with HBeAG status whereas AA genotype did not show any association (p = .663). Also,GG and GC genotypes of IL-18(-137) showed significant (p < 0.001) positive association and significant (p < 0.001) negative association respectively with HBeAG status and CC genotype showed no association.
Table 4
Association between IL-18 (-607C > A) & (-137G > C) genotypes and HBeAG status
| HBeAg | | | | | |
Genotypes | Neg. (n) | Pos. (n) | χ 2 | p-value | OR | 95% CI |
IL-18(-607) | | | | | | |
CC CA AA | 13 65 3 | 83 51 7 | 0.000 0.000 0.633 | < 0.000 < 0.000 0.633 | 7.485 0.139 1.358 | 3.786–14.798 0.073–0.226 0.341–5.404 |
IL-18(-137) | | | | | | |
GG GC CC | 65 100 9 | 47 7 3 | 0.000 0.000 0.979 | < 0.000 < 0.000 0.979 | 7.882 0.104 1.019 | 3.729–16.660 0.044–0.241 0.266–3.899 |
OR, odd”s ratio : CI, Confidence interval ; χ 2 test for p-Value; ***p < 0.001 means statistically significant. Neg. (HbeAg negative) and Pos. (HbeAg Positive) |
Analysis of association between genotypes of IL-18 gene [-607C > A] and [-137 G > C] and biochemical parameters:
Analysis of associations between IL-18 (-137) genotypes and biochemical markers showed that levels of ALT (alanine transaminase), AST (aspartate transaminase) and ALP (alkaline phosphatase), TP [total protein] and ALB (albumin) had no significant difference among patients having CC, GC, GG genotypes. Significant association (p < 0.05) was, however, found among IL-18(-607) CA and CC genotypes with AST and TP levels as shown in Table 5.
Table 5
Association between genotypes of IL-18 (-137 & -607) and biochemical parameters
IL-18 (137- genotype) | AST | ALT | ALP | TP | Albumin |
CC | 27.4 (19–46) | 37(11–52) | 88(56–153) | - | 4.9(0.1-8) |
GC | 43(3-1850) | 43(9-1563 | 143(1.1–564) | 7.5(0.3–22) | 4.6(2.3–8.5) |
GG | 45(17-2440) | 53.5(3-1320) | 132(1-830 | 6.8(3.7–28) | |
P value | 0.23a | 0.42b | 0.16b | 0.56a | 0.72a |
IL-18 (607- genotype) | | | | | |
CA | 37(13-1850) | 48.4(3-1319) | 133(1.1–564) | 11.2(4.6–111) | 5(1.65–11.2) |
CC | 110(15-2440 | 36(10-1320) | 139(1.0-352 | 6.9(3.0–28) | 4(2.3–8.10) |
P value | 0.001a*** | 0.37a | 0.83a | 0.01a** | 0.09a |
p-value obtained by a Kruskal wallis test (significance between 3 groups) ;***p < 0.001, and bMann- Whitney test ( significance between 2 groups ). Data represented as a median value (q1-q2). |
Analysis of circulating IL-18 levels and its association with IL-18 genotypes
Inappropriate production of IL-18 contributes to the pathogenesis in various types of cancers and may affect the clinical outcome of patients [17]. So, serum IL-18 levels may have some prognostic significance. Thus, accordingly levels of IL-18 were quantified in serum samples of patients at different stages of infection of HBV and comparison with normal healthy controls was done. The mean levels of circulating IL-18 expressed as pg/ml were significantly increased in inactive carrier (58.98 ± 24.49; P < 0·05), hepatitis (61.90 ± 37.89; P < 0.01), HBV-related cirrhosis (70.51 ± 32.10; P < 0.001), and HBV-HCC patients (76.44 ± 22.22 pg/mL; P < 0·001) as compared to the normal healthy controls (43.23 ± 12.35). Also, significant difference was observed in IL-18 levels in inactive carrier (P < 0·001) and hepatitis (P < 0·05) patients when compared to HCC group. The representation of data of IL-18 as median ± interquartile range is shown in Fig. 2a.Further we investigated correlation between serum IL-18 levels with its genotypes, we observed no association between circulating cytokine levels (IL-18) and their associated genotypes as presented in Fig. 2b.
Analysis of levels of signal transducers (pSTAT1 and pNF-κB) in IL-18 stimulated PBMCs
Protein expression of pSTAT1 in isolated PBMCs stimulated by IL-18 in various categories revealed a consistent and significant increase in the expression level of pSTAT as the disease progressed from inactive carrier to HCC. Approximately 2-fold increase in the activated STAT was observed in HCC and cirrhosis categories as compared to control subjects as depicted in fig .3a. Moreover, a significant elevation in the levels of expression of pNFkB in stimulated PBMCs in hepatitis, cirrhosis and HCC as compared to healthy control was observed as shown in Fig. 3b.